Nanoparticle Drug Delivery More Effective Treating Cancer

Article

Nanoparticles selectively target tumor vessels or cancerous cells.

Nanoparticle targeted drug therapy has been found to be a better option for treating cancer in compared with surgery, radiotherapy, and chemotherapy.

Cancer is the leading cause of death globally, especially in underdeveloped countries, where 82% of the world’s population resides.

It’s expected that by 2030, new cancer diagnoses will increase to 21.7 million and cancer-related deaths will increase to 13 million. This is largely because of population growth and aging.

Although chemotherapy has been found to be the best option in terms of efficacy for treating cancer, especially in those with advanced stage disease, it still destroys healthy tissues and results in systemic toxic reactions.

In order to combat these adverse events, researchers believe targeted drug therapy can work as a possible solution. This form of therapy offers a safer option for delivering toxic medication to the cancerous cells site.

Nanoparticles have an advantage because of their extremely small size. This system shows the potential to be a superior treatment option by selectively targeting tumor vessels or cancerous cells. This is done through the delivery of therapeutic genetic modulators or by incorporating novel or standard anticancer drugs.

This study, published in Current Biotechnology, gives a more clear understanding of the different drug loaded nanocarriers, which provides a unique set of chemical, physical, and photonic properties that better delivery drugs to the tumor tissues.

Related Videos
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
© 2024 MJH Life Sciences

All rights reserved.